Patents by Inventor Paul Sheahan
Paul Sheahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8492365Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: June 9, 2009Date of Patent: July 23, 2013Assignees: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
-
Publication number: 20120283201Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: July 12, 2012Publication date: November 8, 2012Applicants: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Jimmy Dumornay, Glen Rennie, Gui Liu, Darrell J. Koza, Paul Sheahan, Karen Stapleton, Paul Hawkins, Beena Bhalie, Atul K. Verma, Laura Honeyman, Tadeusz Warchol, David Messersmith
-
Patent number: 8048867Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: May 4, 2004Date of Patent: November 1, 2011Assignees: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Jimmy Dumornay, Glen Rennie, Gui Liu, Darrell J. Koza, Paul Sheahan, Karen Stapleton, Paul Hawkins, Beena Bhatia, Atul K. Verma, Laura McIntyre, Tadeusz Warchol, David Messersmith
-
Publication number: 20110086822Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: October 8, 2010Publication date: April 14, 2011Inventors: Mark L. Nelson, Kwasi Ohemeng, Roger Frechette, Paul Abato, Victor Amoo, Upul Bandarage, Joel Berniac, Beena Bhatia, Jackson Chen, Mohamed Y. Ismail, Oak Kim, Laura Honeyman, Rachid Mechiche, Andre Pearson, Laxma Reddy Nagavelli, Paul Sheahan, Atul K. Verma, Peter Viski, Tadeusz Warchol
-
Publication number: 20100160263Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: November 12, 2009Publication date: June 24, 2010Applicant: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy Nagavelli, Karen Stepleton, Tad Warchol, Paul Sheahan
-
Patent number: 7696186Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: December 16, 2003Date of Patent: April 13, 2010Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy, Karen Stapleton, Tadeusz Warchol, Paul Sheahan
-
Publication number: 20090325908Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: January 9, 2009Publication date: December 31, 2009Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Jimmy Dumornay, Glen Rennie, Gui Liu, Darrell J. Koza, Paul Sheahan, Karen Stapleton, Paul Hawkins, Beena Bhatia, Atul K. Verma, Laura Honeyman, Tadeusz Warchol, David Messersmith
-
Publication number: 20090306022Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: June 9, 2009Publication date: December 10, 2009Applicants: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
-
Patent number: 7595309Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: May 24, 2004Date of Patent: September 29, 2009Assignees: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Beena Bhatia, David Messersmith, Mohamed Y. Ismail, Todd Bowser, Laura McIntyre, Darrell J. Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul K. Verma, Tadeusz Warchol, Upul Bandarage
-
Publication number: 20050038002Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: December 18, 2003Publication date: February 17, 2005Applicant: Paratek Pharmaceuticals, Inc.Inventors: Mark Nelson, Kwasi Ohemeng, Roger Frechette, Paul Abato, Victor Amoo, Upul Bandarage, Joel Berniac, Beena Bhatia, Jackson Chen, Mohamed Ismail, Oak Kim, Laura Honeyman, Rachid Mechiche, Andre Pearson, Laxma Nagavelli, Paul Sheahan, Atul Verma, Peter Viski, Tadeusz Warchol
-
Publication number: 20040224928Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: May 24, 2004Publication date: November 11, 2004Applicants: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
-
Publication number: 20040214801Abstract: The present invention pertains, at least in part, to novel 9- substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: May 4, 2004Publication date: October 28, 2004Applicants: Paratek Pharmaceuticals, Inc., Trustees of Tufts CollegeInventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Jimmy Dumornay, Glen Rennie, Gui Liu, Darrell Koza, Paul Sheahan, Karen Stapleton, Paul Hawkins, Beena Bhatia, Atul K. Verma, Laura McIntyre, Tadeusz Warchol, David Messersmith
-
Publication number: 20040138183Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: December 16, 2003Publication date: July 15, 2004Applicant: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy, Karen Stapleton, Tadeusz Warchol, Paul Sheahan
-
Patent number: 6683068Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: June 29, 2001Date of Patent: January 27, 2004Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy, Karen Stapleton, Tad Warchol, Paul Sheahan
-
Publication number: 20030125348Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: June 29, 2001Publication date: July 3, 2003Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Jimmy Dumornay, Glen Rennie, Gui Liu, Darrell Koza, Paul Sheahan, Karen Stapleton, Paul Hawkins, Beena Bhatia, Atul K. Verma, Laura McIntyre, Tadeusz Warchol, David Messersmith
-
Publication number: 20030055025Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: June 29, 2001Publication date: March 20, 2003Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
-
Publication number: 20020193354Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: June 29, 2001Publication date: December 19, 2002Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy, Karen Stapleton, Tad Warchol, Paul Sheahan